Tianying Wu | Oncology and Precision Medicine | Innovative Research Award

Published on by Oncology

“`html

Innovative Research Award

Tianying Wu
San Diego State University, United States

Tianying Wu
Affiliation San Diego State University
Country United States
Scopus ID 56174751700
Documents 51
Citations 1843
h-index 21
Subject Area Oncology and Precision Medicine
Event International Research Awards on Oncology and Cancer Research
ORCID 0000-0003-1679-3511

The Tianying Wu recognizes scholarly excellence demonstrated through impactful scientific investigations, sustained publication activity, and meaningful contributions to oncology and precision medicine. Tianying Wu of San Diego State University has established an academic profile characterized by interdisciplinary collaboration, high-quality publications, and measurable research influence within cancer-related biomedical sciences. The available scholarly indicators, including publication output, citation performance, and h-index, reflect consistent engagement in internationally recognized research activities.[1] [2]

Abstract

Tianying Wu’s academic profile reflects a productive research career in oncology and precision medicine supported by peer-reviewed publications and significant scholarly citations. The integration of laboratory research, translational science, and interdisciplinary collaboration contributes to advancing understanding of cancer biology and therapeutic strategies. Bibliometric indicators demonstrate sustained scientific visibility and academic engagement across international research communities.[1] [3]

Keywords

Oncology, Precision Medicine, Cancer Biology, Translational Research, Molecular Oncology, Biomarkers, Personalized Medicine, Clinical Research, Biomedical Science, Cancer Therapeutics.

Introduction

Modern oncology research increasingly emphasizes precision medicine approaches that integrate genomic discoveries with individualized patient care. Researchers working in this field contribute to improving diagnostic accuracy, therapeutic selection, and long-term clinical outcomes. Academic achievements are commonly evaluated using publication quality, citation metrics, collaborative research, and contributions to scientific innovation. Tianying Wu’s scholarly profile aligns with these internationally recognized indicators of academic excellence.[2] [4]

Research Profile

Affiliated with San Diego State University, Tianying Wu has developed an academic portfolio spanning oncology and precision medicine. The available Scopus metrics indicate 51 indexed publications, 1,843 citations, and an h-index of 21, reflecting sustained scholarly influence and consistent scientific productivity. Such metrics are widely used for assessing research visibility and long-term academic impact across biomedical disciplines.[1]

Research Contributions

Research contributions associated with this academic profile include participation in studies related to cancer biology, molecular mechanisms, translational medicine, and precision oncology. Such investigations support improved understanding of disease progression and therapeutic response while encouraging evidence-based clinical applications. Collaborative scientific research remains fundamental for accelerating innovation within modern oncology.[3] [5]

Publications

The publication record demonstrates sustained engagement with peer-reviewed scientific literature. Indexed articles contribute to ongoing discussions in oncology, biomedical research, and precision medicine while supporting future investigations through reproducible scientific methodologies. Citation performance further indicates continued academic relevance within the international research community.[1]

Research Impact

Research impact extends beyond publication counts by influencing scientific dialogue, interdisciplinary collaboration, and evidence-based healthcare. Citation metrics, h-index values, and continued referencing by other investigators collectively indicate scholarly visibility. These indicators provide objective evidence supporting recognition within competitive academic award programs.[2] [4]

Award Suitability

Based on publicly available academic indicators, Tianying Wu demonstrates qualifications consistent with consideration for the Innovative Research Award presented through the International Research Awards on Oncology and Cancer Research. Evaluation criteria including publication productivity, scholarly citations, research quality, interdisciplinary engagement, and measurable academic influence collectively support recognition within an international academic framework.[1] [5]

Conclusion

The scholarly profile of Tianying Wu reflects sustained academic productivity, meaningful citation performance, and ongoing engagement with oncology and precision medicine research. These measurable indicators represent important components of scientific excellence and support recognition through academic award initiatives dedicated to advancing cancer research and international scholarly collaboration.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Tianying Wu, Author ID 56174751700. Scopus.https://www.scopus.com/pages/authors/56174751700
  2. ORCID. (n.d.). Researcher Profile: Tianying Wu.https://orcid.org/0000-0003-1679-3511
  3. Crossref. (n.d.). Digital Object Identifier Handbook.https://doi.org/10.1038/nature
  4. National Cancer Institute. (n.d.). Precision Medicine in Cancer Treatment.https://www.cancer.gov/research/areas/treatment/precision-medicine
  5. International Research Awards on Oncology and Cancer Research. (n.d.). Award Information.https://oncology.pencis.com/

“`

Prof Dr. TatianaTilli – Oncology and Precision Medicine – Women Researcher Award

Published on by Oncology

Prof Dr. TatianaTilli - Oncology and Precision Medicine - Women Researcher Award

Oswaldo Cruz Foundation - Brazil

AUTHOR PROFILE

Google Scholar
Scopus
Orcid

EARLY ACADEMIC PURSUITS

Tatiana Martins Tilli pursued her Doctorate in Medicine from the Instituto Nacional de Câncer (INCA) in Rio De Janeiro, Brazil. Her research focused on the functional characterization of splicing variant isoforms of osteopontin in ovarian and prostate carcinomas. This research was conducted under the guidance of Dr. Etel Rodrigues Pereira Gimba and Dr. Akeila Bellahcène at the Université de Liège during her Sandwich Doctorate. The study highlighted the significance of osteopontin as a molecular marker in ovarian and prostate cancers, emphasizing the role of splicing isoforms.Prior to her doctorate, Dr. Tilli completed her Master's in Medicine at INCA. Her research focused on autoantibodies against osteopontin as potential serum markers in neoplasms. This research further underscored the importance of osteopontin as a molecular marker in oncology and provided insights into its immunological aspects.

PROFESSIONAL ENDEAVORS

After completing her doctorate, Dr. Tilli pursued her postdoctoral research at the University of Alberta in Edmonton, Canada. Her postdoctoral work encompassed areas such as Systems Biology, Cellular Biology, and Molecular Biophysics. This period allowed her to expand her research expertise and collaborate with international experts in her field.Currently, Dr. Tilli serves as a public servant in a full-time and exclusive capacity, dedicating 40 hours weekly as a researcher. Her role involves conducting research in the domain of human health, building on her extensive academic background and professional experience.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Dr. Tilli's research has primarily revolved around osteopontin, a molecule of significant interest in oncology. Her studies have explored the functional characterization of splicing variant isoforms of osteopontin and the potential of autoantibodies against osteopontin as serum markers in neoplasms. These research endeavors have contributed significantly to the understanding of molecular markers in ovarian and prostate cancers.

IMPACT AND INFLUENCE

Dr. Tilli's work has had a substantial impact on the field of oncology, particularly in the identification and characterization of molecular markers in ovarian and prostate cancers. Her research findings have been influential in shaping the current understanding of osteopontin's role in cancer biology and its potential applications in diagnostic and therapeutic strategies.

LEGACY AND FUTURE CONTRIBUTIONS

Dr. Tatiana Martins Tilli has established herself as a leading researcher in the field of oncology, with a focus on molecular markers, particularly osteopontin. Her legacy lies in her significant contributions to understanding the role of osteopontin in ovarian and prostate cancers.In the future, Dr. Tilli is expected to continue her groundbreaking research, further exploring the potential applications of osteopontin and its variants in cancer diagnosis, prognosis, and targeted therapy. Her continued dedication to advancing the field of oncology promises to yield further impactful contributions to human health.

NOTABLE PUBLICATIONS

Unlocking Overexpressed Membrane Proteins to Guide Breast Cancer Precision Medicine. 2024

Aptamer-Based Recognition of Breast Tumor Cells: A New Era for Breast Cancer Diagnosis. 2024

Biotechnological Evolution of siRNA Molecules: From Bench Tool to the Refined Drug. 2022

Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making. 2021

Epidermal growth factor receptor regulates fibrinolytic pathway elements in cervical cancer: functional and prognostic implications. 2021

Prof Dr.Isabel Heidegger – Oncology and Precision Medicine – Best Researcher Award

Published on by Oncology

Prof Dr.Isabel Heidegger - Oncology and Precision Medicine - Best Researcher Award

Medizinische Universität Innsbruck - Austria

AUTHOR PROILE

Scopus

EARLY ACADEMIC PURSUITS:

Isabel Heidegger commenced her academic journey with a strong foundation in the field of medicine. She pursued her early education with a focus on urology, setting the stage for her future contributions to the medical community.

PROFESSIONAL ENDEAVORS:

Isabel Heidegger's professional journey has been marked by significant achievements. Joining the Department of Urology at the Medical University Innsbruck in 1984, she steadily progressed in her career. Currently holding the distinguished position of Professor of Translational Prostate Cancer Therapy and Deputy Director of the Department of Urology, her leadership is evident in both clinical and research aspects.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Heidegger has made substantial contributions to the field of oncology and precision medicine, with a primary focus on translational prostate cancer therapy. Her work encompasses both basic-translational and clinical science. Her dedication to prostate cancer research extends to conservative and surgical treatment modalities.

IMPACT AND INFLUENCE:

As a physician-scientist specializing in prostate cancer, Heidegger's impact reverberates through her extensive research and clinical endeavors. Her commitment to advancing knowledge and improving patient outcomes has positioned her as a key influencer in the domain of urology.

ACADEMIC CITES:

Isabel Heidegger's work has garnered recognition in academic circles, evident in her citations and contributions to scholarly publications. Her research findings and clinical insights have contributed to the academic discourse in urology and prostate cancer treatment.

LEGACY AND FUTURE CONTRIBUTIONS:

Heidegger's legacy is shaped by her tireless pursuit of excellence in prostate cancer research and therapy. Her ongoing contributions lay the groundwork for future advancements in urology. The impact of her work is poised to endure, leaving a lasting legacy in the realm of translational medicine and prostate cancer treatment.

NOTABLE PUBLICATION

STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.2023

Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.2022

 

 

-